Untitled

Ocular Update
Howard D Pomeranz
Rachel E Sobel
only two (five per cent) patients recovered vision.The vision outcome was unknown inthe remaining two (five per cent) men.
occurring in men being treated for erectile treated with PDE-5 inhibitors are rare, but sildenafil accounts for about one-fifth of all drug-associated ischemic optic neuropathy.
Despite the limitations of this review, we believe the information demonstrates there is the potential for serious ocular toxicity associated with PDE-5 inhibitor treatment, first using these drugs.That conclusion also observational studies demonstrate that the seems consistent with the decision by the incidence of nonarteritic anterior ischemic inhibitors include information on reports of (Viagra, Pfizer) is no higher than the rate Laties, MD, G Scheie research professor of associate professor of ophthalmology, New York University, New York, and specialises in University of Pennsylvania Medical School, Philadelphia, and co-authors from Pfizer.
inhibitor-associated optic neuropathy werepresented at the annual meeting of ARVO.
published literature and from the UnitedStates Food and Drug Administration’s (FDA) MedWatch program that describedclinical characteristics of optic neuropathy occurring in men treated with sildenafil ortadalafil (Cialis, Lilly ICOS). Cases were contained clinical information indicating thedevelopment of optic disc oedema, visual field defects, optic disc atrophy, optic dischaemorrhages, afferent pupillary defect, and/or change in visual acuity or visionblurring.
identified. Only the literature report was Howard D Pomeranz MD,PhD
accounted for about half of the remaining another limitation of this review is that it posterior ischemic optic neuropathy.
often missing on the duration of treatment The findings in nearly all patients included of sildenafil- or tadalafil-associated optic professionals to get a careful drug history decrease in visual acuity or vision blurring ingestion and presentation (33 per cent).
(85 per cent).Visual field defects (59 per neuropathy with the aim of identifying PDE- cent) and optic disc oedema (54 per cent) inhibitor use ranged from a single dose to added to the existing pool. In addition, they features, while 14 patients (36 per cent) more than one year.Time to onset of visual were reported to present with an afferent identify approaches that could be used to develop this complication in one eye that pupillary defect and optic disc haemorrhage was reported in 11 patients (28 per cent).
information was reported, but potentially exploration would be to analyse data from ranged in age from 34 to 76 years old, with a median of 61.5 years. Sildenafil accounted contained much less detailed information.
that information available, the majority had for all of the 21 reports to MedWatch and identifying men with a diagnosis of ischemic unilateral involvement (85 per cent), mostly for 15 of the 18 literature reports (83 per optic neuropathy and those who received a prescription for a PDE-5 inhibitor. He also incomplete and highlight the limitations of pointed out that attempts to estimate the suffered permanent loss of vision in one (77 per cent) or both (13 per cent) eyes, while cent), while non-specified ischemic optic standardised examination,” he said.
account individual susceptibility based on Ocular Update
optic disc characteristics, ie, presence of the 50 years and older was about 2.5 cases per confounders need to also be controlled for symptoms of NAION developing amongmen being treated with PDE-5 inhibitors,the incidence of that occurrence isunknown.These analyses show that in large Slowdown for ruboxistaurin
Perimeter.The new LD700 Perimeter will be built by Tinsley and marketed by Paradigm The US FDA told Eli Lilly and Company that globally.The LD700 has already received US additional clinical trials.The FDA is asking “The clinical trials provide an opportunity Lilly to conduct an additional three-year Scan/Pachymeter, and two A/B Scan devices.
to reliably capture incident serious adverse study of the experimental oral treatment for events, and the epidemiologic assessments diabetic retinopathy. Lilly was seeking an involving large numbers of individuals have indication for the treatment of moderate-to- Bausch develops plasmin options
considerable power. As such this analysis severe nonproliferative diabetic retinopathy.
Ruboxistaurin is a specific inhibitor of PKC b, recombinant plasmin technology for use in risk that is very difficult to derive from Howard D Pomeranz MD,PhD
individual, spontaneous case reports, and it consider its options, but does not intend to developed rPlasmin, a recombinant derivative is a perspective that warrants attention.” withdraw its new drug application. Earlier this year Lilly signed an agreement with Alcon to Defining the incidence
seriously, so this analysis was performed to proteins, including fibrin clots. Bausch believes the technology has the potential to treat derived from 103 Pfizer-sponsored sildenafil was reassuring to see that with more than surgery is now used.The company says it is observational, “real-life” studies – the Pfizer- AMO shipping new Tecnis
now developing plasma-derived plasmin for sponsored prospective International Men’s ocular indications. It is enrolling patients in found to be consistent with what would be new Tecnis CL silicone IOL in the US, Canada early-stage clinical trials to evaluate plasmin’s and Asia.The company introduced the lens at general population,” said Rachel E Sobel the XXIV Congress of the ESCRS in London.
MPH, associate director of epidemiology in Safety Research Unit at the University of recombinant version. Bausch agreed to make company says the new IOL has blue-modified included open-label and double-blind trials C PMMA haptics that provide better visibility and easier implantation of the lens. It also has patient-years of observation) treated for a frosted OptiEdge design, which is said to ED with sildenafil between 1993 and 2003.
opacification.The new IOL is already available in Europe and will be marketed in Japan next New blade box from Schwind
Schwind eye-tech-solutions has developed a with nearly 3,000 patient-years of follow-up who received a prescription for sildenafil Pfizer expands AMD research
enhanced safety during treatment.The blade is guided and protected during insertion and sildenafil through the United Kingdom’s Biotech to acquire an exclusive worldwide license to Quark’s novel human gene RTP- the surgeon, thus avoiding the risk of injuries and complications, the company says.
contributed about 35,500 patient-years of expression or function. RTP-801 is involved vessels that accelerate the progression of Gene therapy in the works
incident cases of NAION during sildenafil age-related macular degeneration. Financial treatment identified a single affected patient agreement with Brazil’s Institute of Vision to develop gene-based treatments for Leber’s Rachel E Sobel MPH
clinical trials or the IMHS. Across the entire disease arises from impairments in energy PEM study, the unadjusted incidence rate of Da Vinci femto laser renamed
the PEM involved a 61-year-old patient who had multiple other risk factors for NAION, worldwide research consortium is involved analysis to only the second cohort of men “Ziemer’s Femto” Laser Device, model inherited mitochondrial diseases. LHON is an occurred, the incidence rate was similar at hyperlipidemia, and ischemic heart disease, attractive target because researchers have 3.0 cases per 100,000 patient-years.
including a prior myocardial infarction. He identified the genes believed responsible for Dr Laties observed those calculated rates was also taking multiple other medications the disorder.Although LHON is quite rare, compare favourably with literature reports and had been using sildenafil for over a year New compact perimetry tool
before experiencing symptoms of NAION.
treatment for that disease could advance the aged 50 years and older. In a population- Hartest Precision Instruments Ltd., regarding

Source: http://www.escrs.org/PUBLICATIONS/EUROTIMES/06Nov/pdf/StudiesevaluateViagra.pdf